arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

CRISPR Therapeutics AG

CRSP

$53.51 ▲ +1.90 (+3.68%) at close

13 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

CRISPR Therapeutics AG faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8B

Dividend Yield —

Revenue Growth -90.6% →

Op. Margin None

ROIC -34.8% ↘

FCF / Share $-3.85 ↘

Trailing P/E —

Price / Book 2.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.51M

↓ -90.6% —

Net Income Profit after all expenses

$-581.60M

↓ -58.8% —

Operating Margin Operating profit as % of sales

-60.0%

↓ -246.8% —

FCF / Share Free cash flow per share

$-3.85

↓ -124.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	-90.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1232%)	-89.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1224%)	30885.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+385968%)	-99.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1348%)	127154.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1589337%)	-99.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1347%)	9169.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+114523%)	-92.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1255%)	693.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+8574%)	1990.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+24784%)	—	—	—
EPS Growth YoY (%)	-49.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-123.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	76.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	N/M	N/M	—	—	—	—	—	—
Net Income Growth YoY (%)	-58.8% Weak ↓ Weak Declining Year-over-year change in net income	-138.4% Weak Weak Year-over-year change in net income	76.4% Excellent Excellent Year-over-year change in net income	N/M	N/M	N/M	N/M	-141.4% Weak ↑ Weak Improving Year-over-year change in net income	-194.9% Weak ↓ Weak Declining Year-over-year change in net income	9.1% Fair Fair Year-over-year change in net income	-263.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-124.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	49.7% Excellent Excellent Year-over-year change in free cash flow	50.3% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	N/M	N/M	—	—	—	—	—	—
Revenue CAGR 3Y (%)	43.1% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	-65.6% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	702.2% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-83.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	564.1% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-74.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	282.8% Excellent Excellent Compound annual revenue growth over 3 years	133.0% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—
Revenue CAGR 5Y (%)	37.3% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	-33.6% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	160.0% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	-50.7% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	181.6% Excellent Excellent Compound annual revenue growth over 5 years	23.8% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Operating Margin (%) (%)	—	—	-60.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-500%)	—	40.8% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+172%)	—	16.1% Fair Fair Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+8%)	—	-157.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1151%)	—	—	—	—
Effective Tax Rate (%) (%)	-0.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.7% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	-41.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-445%)	—	41.3% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+244%)	—	23.1% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+92%)	—	-166.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1489%)	-448.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3840%)	—	—	—
FCF Margin (%) (%)	—	-387.7% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-72.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	50.0% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	17.3% Good Good Free cash flow as a percentage of revenue Optimal: > 10%	—	-190.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.76x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.21x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.14x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	-34.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-35.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	15.5% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-21.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	4.9% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	88.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-29.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	13.6% Good ↑ Good Improving Operating profit relative to total assets Optimal: > 10%	-19.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	4.4% Caution ↑ Caution Improving Operating profit relative to total assets Optimal: > 10%	-32.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-16.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-30.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-302%)	-19.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-226%)	-8.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-154%)	-34.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-331%)	15.7% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	-21.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-240%)	7.1% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-53%)	-42.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-380%)	-36.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-343%)	-10.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	87.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+484%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Net Debt (USD)	$-347.56M	$-298.26M	$-389.48M	$-211.88M	$-923.03M	$-1.17B	$-943.77M	$-456.65M	$-239.76M	$-315.52M	$-155.96M	$-945.00K	$-361.00K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$0.04	$0.44	$4.69	$0.02	$12.05	$0.01	$5.32	$0.07	—	—	—	—	—
Basic EPS, GAAP (USD)	$-6.47	$-4.34	$-1.94	$-8.36	$4.97	$-5.29	$1.23	$-3.44	—	—	—	—	—
Free Cash Flow per Share (USD)	$-3.85	$-1.71	$-3.41	$-6.85	$6.02	$-3.89	$0.92	$-2.06	—	—	—	—	—
Book Value per Share (USD)	$20.04	$22.53	$23.52	$23.89	$31.17	$22.52	$15.46	$7.56	$4.63	$5.86	$-5.26	—	—
Tangible Book Value per Share (USD)	$20.04	$22.53	$23.52	$23.89	$31.17	$22.52	$15.46	$7.56	$4.63	$5.86	$-5.26	—	—
Basic Weighted Avg Shares (shares)	89.93M	84.36M	79.22M	77.75M	75.95M	65.95M	54.39M	47.96M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$1.84B	$1.85B	$1.80B	$1.73B	$2.30B	$1.62B	$930.44M	$438.65M	$233.87M	$298.19M	$146.69M	—	—
Total Equity (USD)	$1.92B	$1.93B	$1.88B	$1.88B	$2.40B	$1.66B	$939.42M	$392.19M	$187.83M	$232.85M	$-29.10M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$3.51M	$37.31M	$371.21M	$1.20M	$914.96M	$719.00K	$289.59M	$3.12M	$41.00M	$5.16M	$247.00K	—	—
Depreciation Expense (USD)	$19.48M	$19.26M	$19.84M	$24.17M	$17.95M	$9.18M	$4.72M	$3.52M	$3.02M	$925.00K	$127.00K	$38.00K	—
Net Income, GAAP (USD)	$-581.60M	$-366.25M	$-153.61M	$-650.17M	$377.66M	$-348.87M	$66.86M	$-164.98M	$-68.36M	$-23.18M	$-25.50M	$-7.01M	—
Operating Cash Flow (USD)	$-345.01M	$-142.77M	$-260.38M	$-495.74M	$538.97M	$-238.37M	$56.68M	$-96.24M	$-70.09M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 45 quarters

CRISPR Therapeutics AG

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CRSP with peers